Jm. Neutel et al., The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension, INT J CL PR, 53(3), 1999, pp. 175-178
This 8-week, open-label study compared the efficacy and safety of once-dail
y telmisartan, either alone or in combination with hydrochlorothiazide (HCT
Z) and amlodipine, with a similar enalapril regimen in patients with severe
hypertension. Clinically relevant reductions in supine systolic blood pres
sure/DBP were observed with telmisartan (14.6/13.2 mmHg) and enalapril (13.
0/12.9 mmHg) monotherapy. Incremental reductions were seen with up-titratio
n of monotherapy (telmisartan 8.1/7.4 and enalapril 9.2/7.7 mmHg), and the
addition of HCTZ (telmisartan 14.9/8.7 and enalapril 8.0/6.7 mmHg), and aml
odipine (telmisartan 8.0/6.5 and enalapril 10.5/6.4). After 8 weeks of trea
tment, supine DBP control was achieved in 55% and 35% of the patients on th
e telmisartan and enalapril regimens, respectively. Both treatment regimens
were well tolerated. Telmisartan, a new angiotensin receptor blocker, is a
safe and effective drug to use in combination for the treatment of patient
s with severe hypertension and proved at least as effective as the enalapri
l combination.